Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis: A prospective multiinstitutional study

Lauren J. Luk, Toby Steele, Jess C. Mace, Zachary M. Soler, Luke Rudmik, Timothy Smith

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: A health utility value represents an individual's preference for living in a specific health state and is used in cost-utility analyses. This study investigates the impact of continuing medical therapy on health utility outcomes in patients with chronic rhinosinusitis (CRS). Methods: The Medical Outcomes Study Short Form-6D (SF-6D) questionnaire was administered to patients prospectively enrolled in a longitudinal study examining treatment outcomes for CRS. Patients were prescribed robust, initial medical therapy and then elected to continue with medical therapy (n = 40) or undergo endoscopic sinus surgery (ESS), followed by medical therapy (n = 152). Patients observed through treatment crossover to ESS were also evaluated (n = 20). Health utility values (SF-6D) were generated at baseline, 6-months, and 12-months follow-up for both cohorts and evaluated using repeated measures analysis of variance (ANOVA). Results: Treatment crossover patients were found to have a significantly higher prevalence of previous sinus surgery compared to medical management (χ2 = 6.91; p = 0.009) and surgical intervention (χ2 = 8.11; p = 0.004) subgroups. Mean baseline utility value for the medical therapy cohort was significantly better compared to the ESS cohort (mean ± standard deviation; 0.76 ± 0.12 vs 0.70 ± 0.15; p = 0.023). Significant improvement in health utility was reported in the ESS cohort (F(2) = 37.69; p <0.001), whereas values remained stable, without significant improvement, in both the medical therapy cohort (F(2) = 0.03; p = 0.967) and treatment crossover cohort (F(2) = 2.36; p = 0.115). Conclusion: Patients electing continued medical management report better baseline health utility compared to patients electing ESS. Patients electing ESS show significant improvement in health utility, whereas those electing continued medical management demonstrate stable health utility over 12 months.

Original languageEnglish (US)
Pages (from-to)1018-1027
Number of pages10
JournalInternational Forum of Allergy and Rhinology
Volume5
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Prospective Studies
Health
Therapeutics
Cost-Benefit Analysis
Longitudinal Studies
Analysis of Variance
Outcome Assessment (Health Care)

Keywords

  • Chronic disease
  • Cost-effectiveness
  • Endoscopy
  • Health utility
  • Medication therapy management
  • Quality of life
  • Sinusitis
  • Therapeutics
  • Utility

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis : A prospective multiinstitutional study. / Luk, Lauren J.; Steele, Toby; Mace, Jess C.; Soler, Zachary M.; Rudmik, Luke; Smith, Timothy.

In: International Forum of Allergy and Rhinology, Vol. 5, No. 11, 01.11.2015, p. 1018-1027.

Research output: Contribution to journalArticle

@article{3d121cbc1e5148bf8bc36e30e6803df7,
title = "Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis: A prospective multiinstitutional study",
abstract = "Background: A health utility value represents an individual's preference for living in a specific health state and is used in cost-utility analyses. This study investigates the impact of continuing medical therapy on health utility outcomes in patients with chronic rhinosinusitis (CRS). Methods: The Medical Outcomes Study Short Form-6D (SF-6D) questionnaire was administered to patients prospectively enrolled in a longitudinal study examining treatment outcomes for CRS. Patients were prescribed robust, initial medical therapy and then elected to continue with medical therapy (n = 40) or undergo endoscopic sinus surgery (ESS), followed by medical therapy (n = 152). Patients observed through treatment crossover to ESS were also evaluated (n = 20). Health utility values (SF-6D) were generated at baseline, 6-months, and 12-months follow-up for both cohorts and evaluated using repeated measures analysis of variance (ANOVA). Results: Treatment crossover patients were found to have a significantly higher prevalence of previous sinus surgery compared to medical management (χ2 = 6.91; p = 0.009) and surgical intervention (χ2 = 8.11; p = 0.004) subgroups. Mean baseline utility value for the medical therapy cohort was significantly better compared to the ESS cohort (mean ± standard deviation; 0.76 ± 0.12 vs 0.70 ± 0.15; p = 0.023). Significant improvement in health utility was reported in the ESS cohort (F(2) = 37.69; p <0.001), whereas values remained stable, without significant improvement, in both the medical therapy cohort (F(2) = 0.03; p = 0.967) and treatment crossover cohort (F(2) = 2.36; p = 0.115). Conclusion: Patients electing continued medical management report better baseline health utility compared to patients electing ESS. Patients electing ESS show significant improvement in health utility, whereas those electing continued medical management demonstrate stable health utility over 12 months.",
keywords = "Chronic disease, Cost-effectiveness, Endoscopy, Health utility, Medication therapy management, Quality of life, Sinusitis, Therapeutics, Utility",
author = "Luk, {Lauren J.} and Toby Steele and Mace, {Jess C.} and Soler, {Zachary M.} and Luke Rudmik and Timothy Smith",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/alr.21588",
language = "English (US)",
volume = "5",
pages = "1018--1027",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Health utility outcomes in patients undergoing medical management for chronic rhinosinusitis

T2 - A prospective multiinstitutional study

AU - Luk, Lauren J.

AU - Steele, Toby

AU - Mace, Jess C.

AU - Soler, Zachary M.

AU - Rudmik, Luke

AU - Smith, Timothy

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: A health utility value represents an individual's preference for living in a specific health state and is used in cost-utility analyses. This study investigates the impact of continuing medical therapy on health utility outcomes in patients with chronic rhinosinusitis (CRS). Methods: The Medical Outcomes Study Short Form-6D (SF-6D) questionnaire was administered to patients prospectively enrolled in a longitudinal study examining treatment outcomes for CRS. Patients were prescribed robust, initial medical therapy and then elected to continue with medical therapy (n = 40) or undergo endoscopic sinus surgery (ESS), followed by medical therapy (n = 152). Patients observed through treatment crossover to ESS were also evaluated (n = 20). Health utility values (SF-6D) were generated at baseline, 6-months, and 12-months follow-up for both cohorts and evaluated using repeated measures analysis of variance (ANOVA). Results: Treatment crossover patients were found to have a significantly higher prevalence of previous sinus surgery compared to medical management (χ2 = 6.91; p = 0.009) and surgical intervention (χ2 = 8.11; p = 0.004) subgroups. Mean baseline utility value for the medical therapy cohort was significantly better compared to the ESS cohort (mean ± standard deviation; 0.76 ± 0.12 vs 0.70 ± 0.15; p = 0.023). Significant improvement in health utility was reported in the ESS cohort (F(2) = 37.69; p <0.001), whereas values remained stable, without significant improvement, in both the medical therapy cohort (F(2) = 0.03; p = 0.967) and treatment crossover cohort (F(2) = 2.36; p = 0.115). Conclusion: Patients electing continued medical management report better baseline health utility compared to patients electing ESS. Patients electing ESS show significant improvement in health utility, whereas those electing continued medical management demonstrate stable health utility over 12 months.

AB - Background: A health utility value represents an individual's preference for living in a specific health state and is used in cost-utility analyses. This study investigates the impact of continuing medical therapy on health utility outcomes in patients with chronic rhinosinusitis (CRS). Methods: The Medical Outcomes Study Short Form-6D (SF-6D) questionnaire was administered to patients prospectively enrolled in a longitudinal study examining treatment outcomes for CRS. Patients were prescribed robust, initial medical therapy and then elected to continue with medical therapy (n = 40) or undergo endoscopic sinus surgery (ESS), followed by medical therapy (n = 152). Patients observed through treatment crossover to ESS were also evaluated (n = 20). Health utility values (SF-6D) were generated at baseline, 6-months, and 12-months follow-up for both cohorts and evaluated using repeated measures analysis of variance (ANOVA). Results: Treatment crossover patients were found to have a significantly higher prevalence of previous sinus surgery compared to medical management (χ2 = 6.91; p = 0.009) and surgical intervention (χ2 = 8.11; p = 0.004) subgroups. Mean baseline utility value for the medical therapy cohort was significantly better compared to the ESS cohort (mean ± standard deviation; 0.76 ± 0.12 vs 0.70 ± 0.15; p = 0.023). Significant improvement in health utility was reported in the ESS cohort (F(2) = 37.69; p <0.001), whereas values remained stable, without significant improvement, in both the medical therapy cohort (F(2) = 0.03; p = 0.967) and treatment crossover cohort (F(2) = 2.36; p = 0.115). Conclusion: Patients electing continued medical management report better baseline health utility compared to patients electing ESS. Patients electing ESS show significant improvement in health utility, whereas those electing continued medical management demonstrate stable health utility over 12 months.

KW - Chronic disease

KW - Cost-effectiveness

KW - Endoscopy

KW - Health utility

KW - Medication therapy management

KW - Quality of life

KW - Sinusitis

KW - Therapeutics

KW - Utility

UR - http://www.scopus.com/inward/record.url?scp=84954400716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954400716&partnerID=8YFLogxK

U2 - 10.1002/alr.21588

DO - 10.1002/alr.21588

M3 - Article

C2 - 26140502

AN - SCOPUS:84954400716

VL - 5

SP - 1018

EP - 1027

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 11

ER -